Global Postmenopausal Vaginal Atrophy Drugs Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Key buying criteria

PART 05: Overview: Vaginal atrophy

• Symptoms
• Causes
• Pathophysiology
• Diagnosis
• Treatment
• Epidemiology

PART 06: Branded drug profiles

• Activella
• Enjuvia
• Estrace
• Femring
• Premarin
• Osphena
• Vagifem

PART 07: Market landscape

• Market overview
• Market size and forecast

PART 08: Market segmentation  by drug class

• Topical estrogen
• Systemic estrogen

PART 09: Geographical segmentation

• Global PVA drugs market by geographical segmentation 2015-2020
• PVA drugs market in Americas
• PVA drugs market in US
• PVA drugs market in EMEA
• PVA drugs market in Europe
• PVA drugs market in APAC
• PVA drugs market in Japan

PART 10: Market drivers

• Significant unmet medical needs
• Favorable healthcare reforms in US
• Increase in awareness of PVA
• Cost-effective OTC drugs

PART 11: Impact of drivers

PART 12: Market challenges

• Patent expiry of branded products
• Low diagnosis rates
• Poor patient adherence
• Side effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

• Paradigm shift to non-estrogenic therapies
• Increased R&D
• Patient assistance programs
• Strategic alliances

PART 15: Vendor landscape

• Competitive scenario
• Market share analysis 2015
• Pfizer
• Allergan
• Shionogi
• Novo Nordisk
• Teva Pharmaceutical
• Other prominent vendors

PART 16: AppendixList of abbreviations

PART 17: Explore Technavio